CN111039939B - 用作蛋白质聚集抑制剂的杂芳基酰胺 - Google Patents

用作蛋白质聚集抑制剂的杂芳基酰胺 Download PDF

Info

Publication number
CN111039939B
CN111039939B CN201911278647.XA CN201911278647A CN111039939B CN 111039939 B CN111039939 B CN 111039939B CN 201911278647 A CN201911278647 A CN 201911278647A CN 111039939 B CN111039939 B CN 111039939B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
asyn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911278647.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111039939A (zh
Inventor
E·M·斯托金
W·赖斯德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Youshibi Biomedical Co ltd
Original Assignee
Youshibi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111039939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Youshibi Biomedical Co ltd filed Critical Youshibi Biomedical Co ltd
Priority to CN201911278647.XA priority Critical patent/CN111039939B/zh
Publication of CN111039939A publication Critical patent/CN111039939A/zh
Application granted granted Critical
Publication of CN111039939B publication Critical patent/CN111039939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201911278647.XA 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺 Active CN111039939B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911278647.XA CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US61/933,246 2014-01-29
US201462078895P 2014-11-12 2014-11-12
US62/078,895 2014-11-12
CN201580017216.1A CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation
CN201911278647.XA CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580017216.1A Division CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Publications (2)

Publication Number Publication Date
CN111039939A CN111039939A (zh) 2020-04-21
CN111039939B true CN111039939B (zh) 2023-09-19

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911278647.XA Active CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
CN201580017216.1A Active CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580017216.1A Active CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Country Status (38)

Country Link
US (3) US9738635B2 (enExample)
EP (2) EP3099684B8 (enExample)
JP (2) JP6619741B2 (enExample)
KR (1) KR102383038B1 (enExample)
CN (2) CN111039939B (enExample)
AP (1) AP2016009347A0 (enExample)
AU (1) AU2015211119B2 (enExample)
BR (2) BR112016017344B1 (enExample)
CA (1) CA2937967C (enExample)
CL (1) CL2016001918A1 (enExample)
CR (1) CR20160394A (enExample)
CY (2) CY1120348T1 (enExample)
DK (2) DK3099684T3 (enExample)
EA (1) EA032374B1 (enExample)
EC (1) ECSP16070327A (enExample)
ES (2) ES2675301T3 (enExample)
HK (1) HK1231470A1 (enExample)
HR (2) HRP20180813T1 (enExample)
HU (2) HUE040274T2 (enExample)
IL (1) IL246987B (enExample)
LT (2) LT3348556T (enExample)
ME (1) ME03800B (enExample)
MX (1) MX2016009896A (enExample)
MY (1) MY187450A (enExample)
NZ (1) NZ722487A (enExample)
PE (1) PE20161393A1 (enExample)
PH (1) PH12016501493B1 (enExample)
PL (2) PL3348556T3 (enExample)
PT (2) PT3348556T (enExample)
RS (2) RS60547B1 (enExample)
SA (1) SA516371579B1 (enExample)
SG (1) SG11201606108RA (enExample)
SI (2) SI3348556T1 (enExample)
SM (2) SMT202000376T1 (enExample)
TR (1) TR201809440T4 (enExample)
UA (1) UA118209C2 (enExample)
WO (1) WO2015116663A1 (enExample)
ZA (1) ZA201605246B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161393A1 (es) 2014-01-29 2017-01-08 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3573981B1 (en) * 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
AU2018212438C1 (en) * 2017-01-26 2021-05-06 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011932A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
WO2018206778A1 (en) * 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JP2020529432A (ja) 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
EP3703730A4 (en) * 2017-10-31 2022-01-12 Loma Linda University METHODS OF TREATMENT OF TRAUMATIC BRAIN LESIONS
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
EP4458824A1 (en) * 2021-12-27 2024-11-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024094731A1 (en) * 2022-11-02 2024-05-10 Ac Immune Sa Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101124216A (zh) * 2004-12-21 2008-02-13 阿斯利康(瑞典)有限公司 杂环MCHr1拮抗剂及其在治疗中的用途
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
EP2155226A2 (en) * 2007-06-14 2010-02-24 The Regents of the University of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
MX2008011696A (es) * 2006-03-15 2008-11-12 4Sc Ag Inhibidores de nf-kb heterociclicos novedosos.
CA2776480A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
CA2867175A1 (en) 2012-03-28 2013-10-03 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
MX2015000618A (es) * 2012-07-16 2015-04-10 Neuropore Therapies Inc Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
PE20161393A1 (es) 2014-01-29 2017-01-08 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011932A2 (pt) 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
AU2018212438C1 (en) 2017-01-26 2021-05-06 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CN101124216A (zh) * 2004-12-21 2008-02-13 阿斯利康(瑞典)有限公司 杂环MCHr1拮抗剂及其在治疗中的用途
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2155226A2 (en) * 2007-06-14 2010-02-24 The Regents of the University of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗稳 ; 赵永梅 ; 田润果 ; 苏亚彬 ; 洪琛 ; .双烟碱衍生物作为胆碱酯酶和β-淀粉样蛋白双功能抑制剂的设计、合成及活性.药学学报.2013,(11),第47-52页. *

Also Published As

Publication number Publication date
MY187450A (en) 2021-09-22
IL246987B (en) 2021-12-01
US11078196B2 (en) 2021-08-03
EP3099684A1 (en) 2016-12-07
EP3099684B8 (en) 2018-07-04
CY1120348T1 (el) 2019-07-10
SA516371579B1 (ar) 2019-07-16
HRP20180813T1 (hr) 2018-07-27
CN106132960B (zh) 2019-12-17
PE20161393A1 (es) 2017-01-08
LT3348556T (lt) 2020-08-10
PL3099684T3 (pl) 2018-09-28
ZA201605246B (en) 2022-05-25
RS57533B1 (sr) 2018-10-31
SMT201800318T1 (it) 2018-07-17
JP2019163321A (ja) 2019-09-26
ES2675301T3 (es) 2018-07-10
BR112016017344A2 (pt) 2017-10-03
SI3099684T1 (en) 2018-08-31
PH12016501493A1 (en) 2017-02-06
NZ722487A (en) 2022-04-29
AU2015211119A1 (en) 2016-08-11
DK3099684T3 (en) 2018-07-16
RS60547B1 (sr) 2020-08-31
AU2015211119B2 (en) 2019-05-30
US20160207912A1 (en) 2016-07-21
HRP20201107T8 (hr) 2020-12-11
JP2017505779A (ja) 2017-02-23
AP2016009347A0 (en) 2016-07-31
PH12016501493B1 (en) 2017-02-06
US20180093979A1 (en) 2018-04-05
IL246987A0 (en) 2016-09-29
SMT202000376T1 (it) 2020-09-10
EP3348556A1 (en) 2018-07-18
DK3348556T3 (da) 2020-08-03
EP3099684B1 (en) 2018-04-04
BR122018001892B1 (pt) 2023-05-02
CA2937967A1 (en) 2015-08-06
BR112016017344B1 (pt) 2023-05-16
CN111039939A (zh) 2020-04-21
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
CN106132960A (zh) 2016-11-16
ES2808978T3 (es) 2021-03-02
LT3099684T (lt) 2018-06-25
CL2016001918A1 (es) 2017-01-13
CA2937967C (en) 2022-07-26
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
TR201809440T4 (tr) 2018-07-23
HUE040274T2 (hu) 2019-03-28
EP3348556B1 (en) 2020-04-29
KR20160113287A (ko) 2016-09-28
PT3099684T (pt) 2018-10-22
HK1231470A1 (zh) 2017-12-22
AU2015211119A8 (en) 2016-12-15
HUE050964T2 (hu) 2021-01-28
ECSP16070327A (es) 2018-05-31
US20190308965A1 (en) 2019-10-10
WO2015116663A8 (en) 2016-09-15
KR102383038B1 (ko) 2022-04-05
SI3348556T1 (sl) 2020-10-30
EA201691529A1 (ru) 2017-01-30
SG11201606108RA (en) 2016-08-30
PL3348556T3 (pl) 2020-11-02
JP6619741B2 (ja) 2019-12-11
HRP20201107T1 (hr) 2020-10-30
CR20160394A (es) 2016-11-01
MX2016009896A (es) 2017-01-11
EA032374B1 (ru) 2019-05-31
JP6783900B2 (ja) 2020-11-11
ME03800B (me) 2021-04-20
PT3348556T (pt) 2020-07-27
ES2808978T8 (es) 2021-03-22
CY1123374T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
CN111039939B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
US10975066B2 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
JP7100043B2 (ja) タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体
JP7100042B2 (ja) タンパク質凝集のモジュレーターとしてのアルコキシビス－ヘテロアリール誘導体
EP3802528B1 (en) Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
HK1230613B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺
HK40023286B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺
HK40023286A (en) Heteroaryl amides as inhibitors of protein aggregation
HK1230613A1 (en) Heteroaryl amides as inhibitors of protein aggregation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023286

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant